Fuzionaire Diagnostics Enters Agreement with McMaster University to Expand Capabilities in Developing Theranostic Radiopharmaceuticals
Fuzionaire Diagnostics, Inc. ("Fuzionaire Dx") today announced a collaborative research agreement with McMaster University ("McMaster") under which theranostic radiopharmaceuticals developed with Fuzionaire Dx's HetSiFA platform will be evaluated at McMaster's comprehensive preclinical nuclear medicine facilities.